CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis Source: Eur Respir J 2006; 27: 460-469 Year: 2006
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019
The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2002; 19: 1124-1127 Year: 2002
Effect of NF-?B inhibitor IMD-1041 on BLM-induced pulmonary fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011
Rolipram, a PDE4 inhibitor, but not prednisolone, inhibited pulmonary neutrophilia induced by intratracheal instillation of IL-8 in mice Source: Eur Respir J 2005; 26: Suppl. 49, 104s Year: 2005
The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019
Effects of rapamycin on bleomycin induced pulmonary fibrosis in rats and analysis of the underlying mechanism Source: Eur Respir J 2007; 30: Suppl. 51, 575s Year: 2007
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
SD-208 an orally active TGF-β1 receptor antagonist inhibits TGF-β1 induced progressive lung fibrosis in rat Source: Annual Congress 2003 - Animal models of lung injury: useful or not? Year: 2003
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Source: Eur Respir J 2007; 29: 976-985 Year: 2007
Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001